This article is more than 5 years old. Information may no longer be current.

Amgen 3Q profit more than doubles

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Biotech company and anemia drugmaker Amgen Inc. reported higher than expected third quarter profit Tuesday, helped by sales of its rheumatoid arthritis drug Enbrel, which increased 17%. Profit more than doubled to $1.1 billion, or $1.41 per share, compared to $454 million, or 50 cents per share, in its first quarter led by CEO Robert Bradway.  Revenue for the quarter rose 10% to $4.32 billion.

"Our business has very good momentum," Bradway said in a conference call.

Anemia drug sales

•    Aranesp (darbepoetin alfa) sales decreased 17%

•    Epogen  (epoetin alfa) sales increased 3%, beating expectations.